MRI in 183 knees: running showed no cartilage damage. Obesity showed up clearly.
A matched study compared recreational runners, non-runners and adults with obesity, one triplet at a time. The first two groups were indistinguishable on structure and function. The third was not.
"Running wrecks your knees" is one of the most durable pieces of folk physiology in circulation, and it has been contradicted by epidemiology for years without losing much ground. A study published on 26 August attacks it from a different angle — not by counting who develops arthritis, but by looking directly at the cartilage of people who have not developed anything yet.
The design
Investigators drew on the 4HAIE cohort to assemble 61 age- and sex-matched triplets: one recreational runner, one non-runner, and one person with a body mass index of 30 kg/m² or above. That gives 183 asymptomatic adults aged 18 to 65, with a mean age difference within each triplet of 214±87 days [s1].
Matching in triplets is the methodological point. Most studies of running and knee health compare runners with everyone else, and "everyone else" differs from runners in age, sex, body mass and a great deal besides. Here each runner is paired with a specific non-runner and a specific person with obesity of the same age and sex, so the comparison is closer to like-for-like.
Each participant had a 1.5 Tesla MRI, from which the authors quantified T2 relaxation times — a compositional measure of cartilage — and graded morphology as Normal versus Abnormal/Degenerated across 12 femorotibial regions. Knee function was assessed with the KOOS questionnaire. Group differences were tested with non-parametric statistics and cartilage morphology examined further by binary logistic regression [s1].
What the scans showed
Runners had significantly higher T2 values than both non-runners and the obesity group in several lateral femoral and tibial regions (p<0.05) [s1]. That is a compositional difference; the authors do not equate it with damage, and the morphology results argue against reading it that way.
On morphology and function, runners and non-runners were indistinguishable: no significant differences in either [s1].
The obesity group separated from both. Prevalence of normal cartilage in the medial central tibia was 75.4% in the obesity group versus 91.8% in runners and 93.4% in non-runners [s1]. Odds of abnormal findings were up to fourfold higher relative to the obesity group — runners versus obesity OR 3.65 (95% CI 1.30 to 10.23), non-runners versus obesity OR 4.65 (1.44 to 14.92) [s1]. KOOS scores were lowest in the obesity group, particularly for Activities of Daily Living (p=0.004) [s1].
The authors' conclusion is stated in exactly those terms: obesity was associated with a higher prevalence of cartilage abnormalities and poorer self-reported function in daily activities, whereas recreational running was not linked to structural or functional impairment [s1].
Where this sits in the literature
A review published in July, covering evidence from 2020 to 2024, describes a U-shaped risk curve for running and knee osteoarthritis: moderate recreational running appears protective compared with both sedentary living and elite, high-volume running [s2]. In people over 50 with existing osteoarthritis, that review reports that running does not accelerate structural damage and reduces pain when load is increased gradually — the "10% rule" of weekly progression [s2].
That review is a narrative synthesis published in a journal with a low editorial barrier, and it should carry correspondingly less weight than the MRI study. It is included here because it describes the shape of the surrounding literature — the U-curve, and the distinction between recreational and elite volumes — that a single cross-sectional cohort cannot establish on its own.
The limits, which are substantial
The MRI study is cross-sectional. It photographs 183 knees at one moment and cannot say what any of them will look like in a decade. Participants were asymptomatic by design, which is a clean way to study early change and also excludes anyone whose running career already ended in a knee problem — a selection effect that runs in favour of running.
Sixty-one per group is not large for a subgroup analysis, and the confidence intervals reflect it: the runner-versus-obesity odds ratio spans 1.30 to 10.23 [s1]. The direction is clear; the magnitude is not. And the cross-sectional design cannot separate cause from consequence in the obesity group, where higher body mass, lower activity and worse knee function are all associated with each other.
What it means for a reader
Nothing about what any individual should do — this is a description of groups, not a prescription. What it changes is the shape of the received wisdom. On these measurements, in these matched triplets, the exposure associated with worse cartilage morphology and worse daily function was body mass, not running mileage [s1].
What to watch is longitudinal follow-up in the same cohort. T2 differences in the lateral compartment among runners are the kind of finding that means nothing or everything depending on what happens next, and only repeat imaging in the same knees will tell which.
Sources
- [s1] Knee Cartilage Composition, Morphology, and Function in Asymptomatic Recreational Runners, Non-Runners, and Obese Adults: A Matched 4HAIE MRI Study. Medicine & Science in Sports & Exercise, 26 August 2026. https://doi.org/10.1249/MSS.0000000000004118
- [s2] Impact of Running on the Risk and Progression of Knee Osteoarthritis: A Review of Current Evidence. Cureus, 10 July 2026. https://doi.org/10.7759/cureus.112416
Sources
- Knee Cartilage Composition, Morphology, and Function in Asymptomatic Recreational Runners, Non-Runners, and Obese Adults: A Matched 4HAIE MRI Study — Medicine & Science in Sports & Exercise , August 26, 2026
- Impact of Running on the Risk and Progression of Knee Osteoarthritis: A Review of Current Evidence — Cureus , July 10, 2026
More on
Weight loss modifies some diseases and is untested in most of the ones it is blamed for
A Lancet review triangulates the evidence linking adiposity to multisystem disease and finds robust trial support in a short list — while an expert panel argues the drugs must be lifelong.
Eating late does change your metabolism. Whether it makes you fatter is less clear.
A tightly controlled crossover trial found late eating increased hunger, cut waking energy expenditure and shifted fat-tissue gene expression. The population data show a 17% higher odds of obesity.
GLP-1 drugs cost roughly $1,000 a month and a few dollars to make
A study estimated semaglutide's class could be produced for under $75 a month; it lists near $1,000. The gap is patent protection, and in the US it runs to 2032.
Which muscles hold their strength through weight loss? A gene hunt
A transcriptomic sub-study of the CALERIE calorie-restriction trial links 151 genes to preserved leg strength during weight loss, independent of how much body mass was lost.